| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424239100 |
Clostridium (e.g., Clostridium tetani, etc.)
| 128 |
| 424241100 |
Escherichia (e.g., Escherichia coli, etc.)
| 9 |
| 424237100 |
Staphylococcus or Streptococcus
| 8 |
| 424240100 |
Bordetella (e.g., Bordetella pertussis, etc.) | 5 |
| 20080279897 | Method of Treating Cellular Damage - The present invention relates generally to a method of modulating hyperglycaemia-induced endothelial cell functioning and agents useful for same. More particularly, the present invention relates to a method of modulating hyperglycaemia-induced vascular endothelial cell functioning by modulating intracellular sphingosine kinase-mediated signalling. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of the adverse vascular endothelial cell functioning associated with conditions characterised by hyperglycaemia, and/or diabetes mellitus, per se. | 11-13-2008 |
| 20090068228 | METHOD OF SEPARATING PROTECTIVE COMPONENTS OF BORDETELLA PERTUSSIS - To provide a method of efficiently separate protective components of | 03-12-2009 |
| 20100255033 | Non-toxic double mutant forms of pertussis toxin as adjuvants - The invention relates to the use of an antigen which is a non-toxic double mutant form of pertussis toxin for the manufacture of a vaccine composition for intranasal administration to induce an immune response against | 10-07-2010 |
| 20120177688 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 07-12-2012 |
| 20120213821 | NOVEL METHOD FOR ISOLATING ENDOTOXINS - The invention concerns a novel method for extracting endotoxins from bacteria, and the use of said method for preparing compositions comprising endotoxins or derivatives thereof designed for human or animal use (scientific, medical usage). | 08-23-2012 |
| 424238100 |
Corynebacterium (e.g., Corynebacterium diphtheriae, etc.) | 4 |
| 20090010966 | MODIFIED DIPHTHERIA TOXINS - The present application relates to compositions of modified diphtheria toxin and fusion proteins containing modified diphtheria toxin that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome, as well as methods of making the compositions. The present application also relates to a polypeptide toxophore from a modified diphtheria toxin, where the modification is at least one amino acid residue at the amino acid residues 6-8, 28-30 or 289-291 of an unmodified native diphtheria toxin. Also described are fusion proteins which contain a modified diphtheria toxin and a non-diphtheria toxin fragment which contains a cell binding portion. The modified diphtheria toxins described can be used for the treatment of a malignant disease or a non-malignant disease. | 01-08-2009 |
| 20100003282 | SYSTEMS AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT - Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems. | 01-07-2010 |
| 20100074922 | Pneumococcal polysaccharide conjugate vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 03-25-2010 |
| 20110097359 | Production of diphtheria toxin | 04-28-2011 |
| Entries |
| Document | Title | Date |
|---|
| 20080199496 | Genes Associated with Leishmania Parasite Virulence - The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania | 08-21-2008 |
| 20080213310 | Use of lytic toxins and toxin conjugates - Agents are provided which are capable of inhibiting the cell division cycle in a target cell of interest. The agents comprise first and second components, wherein the first component is a targeting moiety which is capable of directing the second component to the target cell of interest. The second component is capable of inhibiting the cell division cycle in the target cell of interest. The agents are preferably provided in the form of conjugates, and the second component is preferably a cytolethal distending toxin. Methods for the preparation of the agents, and the use thereof for treating proliferative cell disorders and intracellular pathogens are also provided. | 09-04-2008 |
| 20090010965 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin - The present invention provides a method for providing a muscle relaxant, wherein said muscle relaxant is a reconstituted solution comprising the neurotoxic component of botulinum toxin free of complexing proteins, which exhibits at least one of the following characteristics, more preferably all characteristics a) to d):
| 01-08-2009 |
| 20090028905 | METHOD FOR TREATMENT OF LAMINITIS IN ANIMALS - The present invention generally relates to methods for treating the sequela of laminitis in hoofed animals. Benefits are obtained by administering to the animals to be treated injections of Botulinum Toxin in the limb to be treated. In one embodiment, about 100 Units to 600 Units of Type A Botulinum Toxin is injected in multiple injections into the flexor digitorum profundus muscle of an animal's affected limb. | 01-29-2009 |
| 20090081256 | TRANSGENIC PLANT-BASED VACCINES - A method of inducing partial or complete immunity to an infectious disease in a mammal comprising providing to the mammal for oral consumption an effective amount of a protein complex comprising five monomeric fusion proteins. | 03-26-2009 |
| 20090104233 | IDENTIFICATION OF RESIDUES CRITICAL FOR THE FUNCTION OF THE VIBRIO CHOLERAE VIRULENCE REGULATOR ToxT BY SCANNING ALANINE MUTAGENESIS - Disclosed are | 04-23-2009 |
| 20090130147 | Capsular polysaccharide solubilisation and combination vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 05-21-2009 |
| 20100008954 | Alpha-galactosyl ceramide analogs and their use as immunotherapies - The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: | 01-14-2010 |
| 20100047284 | METHOD FOR REDUCING SPASMS COMPRISING TREATMENT WITH AN AGENT THAT ELEVATES THE LEVEL OF ONE OR MORE CYCLIC NUCLEOTIDES IN THE MUSCLE - This invention relates to methods for preventing or reducing spasms in smooth muscle, using an agent that elevates the level of one or more nucleotide in the muscle, or an agent which comprises a toxin. The invention also relates to the use of such agents in the manufacture of a medicament for preventing or reducing spasms in smooth muscle. | 02-25-2010 |
| 20100291150 | PSEUDOMONAS EXOTOXIN A CD4+ T-CELL EPITOPES - The present invention provides PE CD4+ T-cell epitopes, as well as novel variants that exhibit reduced immunogenic responses, as compared to the parental PE. The present invention further provides DNA molecules that encode novel PE variants, host cells comprising DNA encoding novel PE variants, as well as methods for making PEs less immunogenic. In addition, the present invention provides various compositions that comprise these PE variants that are less immunogenic than wild-type PEs. | 11-18-2010 |
| 20120003267 | Therapeutic Agents - A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease. | 01-05-2012 |
| 20120128719 | STREPTOCOCCUS VACCINE COMPOSITIONS AND METHODS OF USING THE SAME - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species of the genus | 05-24-2012 |
| 20120141531 | COMPOSITION COMPRISING OIL DROPS - A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant. | 06-07-2012 |
| 20120148624 | MUTANTS OF CHOLESTEROL-DEPENDENT CYTOLYSINS AND USES THEREOF - Mutants of cholesterol-dependent cytolysins comprising at least one amino acid substitution in at least one of Loop 1, Loop 2, or Loop 3 of Domain 4, nucleic acids, vectors, and host cells encoding such polypeptide mutants, and compositions and vaccines comprising such polypeptide mutants. | 06-14-2012 |
| 20140037687 | EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA, METHOD FOR PRODUCING SAME, VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - For the first time, an O-specific polysaccharide antigen that is a | 02-06-2014 |
| 20140294895 | Expression of Protective Antigens in Transgenic Chloroplasts and the Production of Improved Vaccines - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against | 10-02-2014 |
| 20160044900 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 02-18-2016 |
